- Home
- NVGS vs SNDX Comparison
NVGS vs SNDX Comparison
Compare NVGS & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVGS
- SNDX
- Stock Information
- Founded
- NVGS 1997
- SNDX 2005
- Country
- NVGS United Kingdom
- SNDX United States
- Employees
- NVGS N/A
- SNDX N/A
- Industry
- NVGS Marine Transportation
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- NVGS Consumer Discretionary
- SNDX Health Care
- Exchange
- NVGS Nasdaq
- SNDX Nasdaq
- Market Cap
- NVGS 1.1B
- SNDX 1.1B
- IPO Year
- NVGS N/A
- SNDX 2016
- Fundamental
- Price
- NVGS $16.36
- SNDX $14.25
- Analyst Decision
- NVGS Strong Buy
- SNDX Strong Buy
- Analyst Count
- NVGS 3
- SNDX 10
- Target Price
- NVGS $22.00
- SNDX $36.20
- AVG Volume (30 Days)
- NVGS 156.4K
- SNDX 2.0M
- Earning Date
- NVGS 03-12-2025
- SNDX 02-25-2025
- Dividend Yield
- NVGS 1.23%
- SNDX N/A
- EPS Growth
- NVGS 13.48
- SNDX N/A
- EPS
- NVGS 1.12
- SNDX N/A
- Revenue
- NVGS $564,280,000.00
- SNDX $16,000,000.00
- Revenue This Year
- NVGS $0.05
- SNDX N/A
- Revenue Next Year
- NVGS $4.76
- SNDX N/A
- P/E Ratio
- NVGS $14.77
- SNDX N/A
- Revenue Growth
- NVGS 5.99
- SNDX N/A
- 52 Week Low
- NVGS $14.55
- SNDX $12.06
- 52 Week High
- NVGS $18.18
- SNDX $25.34
- Technical
- Relative Strength Index (RSI)
- NVGS 53.99
- SNDX 53.82
- Support Level
- NVGS $16.37
- SNDX $13.40
- Resistance Level
- NVGS $17.25
- SNDX $13.16
- Average True Range (ATR)
- NVGS 0.44
- SNDX 0.70
- MACD
- NVGS -0.01
- SNDX 0.26
- Stochastic Oscillator
- NVGS 38.04
- SNDX 82.02
About NVGS Navigator Holdings Ltd. (Marshall Islands)
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture).
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.